TauRx's HMTM could be the first anti-tau disease-modifying drug for Alzheimer's
TauRx announced topline results from its Phase III LUCIDITY trial evaluating its oral anti-tau product, hydromethylthionine mesylate.
Source: clinicaltrialsarena.com
Page 2 - Sample Services News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Sample Services. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Sample Services Today - Breaking & Trending Today
Study underscores the relationship between social conditions and heart disease
The results could help health professionals and policymakers plan interventions for the most vulnerable diabetic CVD patients.
Source: clinicaltrialsarena.com
Polio outbreak in New York state due to low vaccination coverage
New York has witnessed a polio outbreak due to low vaccination coverage, the urgency of which should be addressed.
Source: clinicaltrialsarena.com
Pipeline Moves: Novartis Phase I/Ib cancer trial terminates, further study chances drop
The Clinical Trials Arena team also investigate assets in radiculopathy, solid tumours, radicular pain, autoimmune disorders and inflammation.
Source: clinicaltrialsarena.com
A disappointing June for Alzheimer's disease, with setbacks for several products
Several companies have announced poor results from clinical trials for Alzheimer’s disease therapies this month.
Source: clinicaltrialsarena.com